» Articles » PMID: 33257838

TRAIL Receptor-induced Features of Epithelial-to-mesenchymal Transition Increase Tumour Phenotypic Heterogeneity: Potential Cell Survival Mechanisms

Overview
Journal Br J Cancer
Specialty Oncology
Date 2020 Dec 1
PMID 33257838
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The continuing efforts to exploit the death receptor agonists, such as the tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), for cancer therapy, have largely been impaired by the anti-apoptotic and pro-survival signalling pathways leading to drug resistance. Cell migration, invasion, differentiation, immune evasion and anoikis resistance are plastic processes sharing features of the epithelial-to-mesenchymal transition (EMT) that have been shown to give cancer cells the ability to escape cell death upon cytotoxic treatments. EMT has recently been suggested to drive a heterogeneous cellular environment that appears favourable for tumour progression. Recent studies have highlighted a link between EMT and cell sensitivity to TRAIL, whereas others have highlighted their effects on the induction of EMT. This review aims to explore the molecular mechanisms by which death signals can elicit an increase in response heterogeneity in the metastasis context, and to evaluate the impact of these processes on cell responses to cancer therapeutics.

Citing Articles

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.


Novel anoikis-related diagnostic biomarkers for aortic dissection based on machine learning.

Zhang H, Ouyang Z, Zhou T, Su F, Wang M Sci Rep. 2024; 14(1):31314.

PMID: 39732886 PMC: 11682115. DOI: 10.1038/s41598-024-82655-6.


The resistance to anoikis, mediated by Spp1, and the evasion of immune surveillance facilitate the invasion and metastasis of hepatocellular carcinoma.

Zhang Z, Chen X, Li Y, Zhang F, Quan Z, Wang Z Apoptosis. 2024; 29(9-10):1564-1583.

PMID: 39066845 PMC: 11416391. DOI: 10.1007/s10495-024-01994-x.


Dual Affinity Nanoparticles for the Transport of Therapeutics from Carrier Cells to Target Cells under Physiological Flow Conditions.

Lopez-Cavestany M, Wright O, Cassidy A, Carter A, King M ACS Omega. 2023; 8(45):42748-42761.

PMID: 38024679 PMC: 10652824. DOI: 10.1021/acsomega.3c05605.


The Prognosis of Cancer Depends on the Interplay of Autophagy, Apoptosis, and Anoikis within the Tumor Microenvironment.

Gulia S, Chandra P, Das A Cell Biochem Biophys. 2023; 81(4):621-658.

PMID: 37787970 DOI: 10.1007/s12013-023-01179-4.


References
1.
Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

2.
Beeman N, Webb P, Baumgartner H . Occludin is required for apoptosis when claudin-claudin interactions are disrupted. Cell Death Dis. 2012; 3:e273. PMC: 3288343. DOI: 10.1038/cddis.2012.14. View

3.
Rachow S, Zorn-Kruppa M, Ohnemus U, Kirschner N, Vidal-Y-Sy S, von den Driesch P . Occludin is involved in adhesion, apoptosis, differentiation and Ca2+-homeostasis of human keratinocytes: implications for tumorigenesis. PLoS One. 2013; 8(2):e55116. PMC: 3563667. DOI: 10.1371/journal.pone.0055116. View

4.
Meyer M, Paquet A, Arguel M, Peyre L, Gomes-Pereira L, Lebrigand K . Profiling the Non-genetic Origins of Cancer Drug Resistance with a Single-Cell Functional Genomics Approach Using Predictive Cell Dynamics. Cell Syst. 2020; 11(4):367-374.e5. DOI: 10.1016/j.cels.2020.08.019. View

5.
Stanisavljevic J, Porta-de-la-Riva M, Batlle R, Garcia de Herreros A, Baulida J . The p65 subunit of NF-κB and PARP1 assist Snail1 in activating fibronectin transcription. J Cell Sci. 2012; 124(Pt 24):4161-71. DOI: 10.1242/jcs.078824. View